Gunasekar, Susheel K.
Xie, Litao
Kumar, Ashutosh
Hong, Juan
Chheda, Pratik R. https://orcid.org/0000-0001-5788-3324
Kang, Chen
Kern, David M. https://orcid.org/0000-0001-8529-9045
My-Ta, Chau
Maurer, Joshua
Heebink, John
Gerber, Eva E. https://orcid.org/0000-0002-1862-3586
Grzesik, Wojciech J.
Elliot-Hudson, Macaulay
Zhang, Yanhui
Key, Phillip
Kulkarni, Chaitanya A.
Beals, Joseph W.
Smith, Gordon I.
Samuel, Isaac
Smith, Jessica K.
Nau, Peter
Imai, Yumi
Sheldon, Ryan D.
Taylor, Eric B. https://orcid.org/0000-0003-4549-6567
Lerner, Daniel J.
Norris, Andrew W. https://orcid.org/0000-0001-8396-9543
Klein, Samuel
Brohawn, Stephen G. https://orcid.org/0000-0001-6768-3406
Kerns, Robert https://orcid.org/0000-0001-5371-403X
Sah, Rajan https://orcid.org/0000-0003-1092-1244
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R43 DK121598, R44 DK126600, R01DK126068, R01DK127080, R01DK106009)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
Article History
Received: 14 January 2021
Accepted: 24 January 2022
First Online: 10 February 2022
Competing interests
: R.S. is co-founder of Senseion Therapeutics, Inc., a start-up company developing SWELL1. modulators for human disease. D.J.L. is co-Founder and CEO of Senseion Therapeutics, Inc. The remaining authors declare no competing interests.